Researchers analyzed 104 patients with type 2 diabetes and found those who switched from insulin to liraglutide and successfully continued taking the drug after one year experienced a significantly lower frequency and dose of insulin at baseline, while those who achieved an A1C level of at least 7% had shorter durations of diabetes and insulin therapy and lower A1C levels at baseline. The findings in Diabetes Therapy revealed those who continued liraglutide therapy for at least one year also had no changes in glycemic control and body weight on average.
Research IDs factors of success of insulin-to-liraglutide switch in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.